HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.
Cutaneous T-cell lymphoma (CTCL) is an uncommon form of non-Hodgkin lymphoma predominantly impacting the skin. It originates in T lymphocytes, a type of white blood cell responsible for immune system function. CTCL manifests as various skin lesions, such as patches, plaques, tumors, or erythroderma, which is widespread redness. The most common subtype of CTCL is mycosis fungoides, characterized by slow-growing, scaly patches on the skin. Sézary syndrome is another subtype, involving widespread reddening and peeling of the skin. The exact cause of CTCL is unknown, and it is not contagious. Diagnosis often involves a combination of clinical evaluation, skin biopsy, and molecular studies. Treatment options vary based on the stage and severity of the disease. Early-stage CTCL may be managed with topical therapies, phototherapy, or skin-directed treatments. Advanced cases may require systemic therapies such as chemotherapy, immunotherapy, or targeted therapies. While CTCL is generally considered indolent, meaning it tends to progress slowly, it can significantly impact the quality of life for affected individuals. The course of the disease varies, and ongoing medical monitoring is crucial for timely intervention. Research is ongoing to better understand the underlying mechanisms of CTCL and to develop more effective treatment strategies for this uncommon but challenging lymphoma.
